



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

19 November 2020
EMA/505373/2020
Press office

Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 09-12 November 2020

During its November 2020 meeting, the CHMP reviewed 6 recommendations for eligibility to PRIME: 3 were granted and 3 were denied.

The individual outcomes adopted this month are listed below.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Eligibility granted

Name*	Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Lacutamab	Biological Medicinal Product	Oncology	Treatment of patients with Sézary Syndrome who have received at least two prior systemic therapies	Nonclinical + Clinical exploratory	Other
Brensocatib	Chemical Medicinal Product	Pneumology-allergology	Treatment of non-cystic fibrosis bronchiectasis	Nonclinical + Clinical exploratory	Other
VAC18193	Biological Medicinal Product	Vaccines	Active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults	Nonclinical + Clinical exploratory	Other

* Name of the active substance, INN, common name, chemical name or company code.

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other types of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.




Eligibility denied

Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Chemical Medicinal Product	Dermatology	Treatment of moderate to severe chronic hand eczema in adults with a history of inadequate response to TCS or when TCS is medically inadvisable	Nonclinical + Clinical exploratory	Other
Advanced Therapy Medicinal Product	Neurology	Treatment of Parkinson's disease	Nonclinical + Clinical exploratory	Other
Biological Medicinal Product	Dermatology	Treatment of atopic dermatitis	Nonclinical + Clinical exploratory	Other

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

Cumulative overview of PRIME eligibility recommendations adopted by 12 November 2020

■ Granted ■ Denied ■ Out of scope*



* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.